Vanguard Group Inc. Buys 48,271 Shares of Progyny, Inc. (NASDAQ:PGNY)

Vanguard Group Inc. grew its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 0.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,692,132 shares of the company’s stock after buying an additional 48,271 shares during the quarter. Vanguard Group Inc. owned 0.10% of Progyny worth $149,939,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. River Road Asset Management LLC purchased a new stake in Progyny during the fourth quarter valued at $25,529,000. Pacer Advisors Inc. increased its position in shares of Progyny by 47.5% during the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock valued at $63,414,000 after purchasing an additional 1,183,558 shares during the last quarter. Fort Washington Investment Advisors Inc. OH increased its position in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after purchasing an additional 695,740 shares during the last quarter. Barclays PLC lifted its stake in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company’s stock worth $11,835,000 after purchasing an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. boosted its holdings in shares of Progyny by 52.2% in the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock worth $22,989,000 after buying an additional 456,853 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on PGNY. Canaccord Genuity Group increased their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. raised their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target for the company in a report on Monday, March 31st. Finally, Bank of America upped their price target on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $23.64.

Progyny Trading Down 5.2 %

NASDAQ:PGNY opened at $21.43 on Tuesday. The stock has a 50-day moving average price of $22.16 and a 200 day moving average price of $18.49. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $36.36. The stock has a market capitalization of $1.83 billion, a P/E ratio of 36.95, a P/E/G ratio of 2.39 and a beta of 1.33.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.